隶属于 默沙东
相关临床试验
3
2 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2015
进行中（未招募）
1
33.3%
尚未招募
1
33.3%
招募中
1
33.3%
暂无批准数据
- CytomX Therapeutics has appointed Rachael Lester as Senior Vice President and Chief Business Officer to lead strategy and business development functions for the company's masked biologics platform. - Lester brings over two decades of experience in biopharmaceutical business development, including previous roles at Replicate Bioscience, Harpoon Therapeutics, and Onyx Pharmaceuticals. - The appointment comes as CytomX advances its clinical pipeline including CX-2051 for colorectal cancer and CX-801 for melanoma, both utilizing the company's PROBODY therapeutic platform. - CytomX's multi-modality platform has produced therapeutic candidates across antibody-drug conjugates, T-cell engagers, and immune modulators with strategic partnerships including Amgen, Bristol Myers Squibb, and Regeneron.
- Hinge Bio has appointed three seasoned biotech executives to key leadership positions to advance its GEM-DIMER platform through clinical development. - The company published preclinical data in Scientific Reports demonstrating that HB2198, a novel anti-CD19/CD20 bispecific antibody, achieves durable depletion of memory B cells in vivo. - HB2198 is designed to treat B cell-mediated autoimmune disorders including systemic lupus erythematosus and is expected to enter clinical trials in the second half of 2025. - The therapeutic candidate demonstrated greater than 99% B cell depletion in preclinical studies, offering potential advantages over CAR-T therapies without associated toxicities.
- Zentalis Pharmaceuticals has appointed James B. Bucher as Chief Legal Officer and Corporate Secretary, effective September 18, 2025, bringing over 30 years of life sciences legal experience. - Bucher previously served as Chief Legal Officer at Harpoon Therapeutics and played a pivotal role in orchestrating the company's acquisition by Merck in 2024. - The appointment comes as Zentalis advances azenosertib, a potentially first-in-class WEE1 inhibitor, into registration-intent clinical trials for ovarian cancer treatment. - Bucher's extensive experience in corporate strategy, mergers and acquisitions, and public company matters will support Zentalis' late-stage development and potential product launch preparations.
- Dr. Rick Austin, with over 25 years of oncology drug development experience, joins VERAXA Biotech as Chief Scientific Officer to advance the company's BiTAC platform and clinical-stage pipeline. - Austin brings extensive expertise from leadership roles at Harpoon Therapeutics, Amgen, and Tularik, where he led tumor immunology projects and enabled numerous IND filings and first-in-human studies. - VERAXA, an emerging leader in novel cancer therapies and proposed acquisition target of Voyager Acquisition Corp., aims to leverage Austin's expertise to expand therapeutic windows for antibody drug conjugates and T-cell engagers.
• Daiichi Sankyo and Merck have expanded their existing partnership to include MK-6070, an investigational DLL3-targeting T-cell engager, with Merck receiving $170 million upfront in the agreement. • MK-6070 targets delta-like ligand 3 (DLL3), which is highly expressed in small cell lung cancer and neuroendocrine tumors, and has received FDA Orphan Drug Designation for SCLC treatment. • The companies plan to evaluate MK-6070 in combination with ifinatamab deruxtecan (I-DXd) in patients with small cell lung cancer, addressing an aggressive cancer with significant unmet treatment needs.
- Artificial Intelligence is revolutionizing clinical trial processes by accelerating data analysis and reducing development timelines, promising faster delivery of life-saving medications to patients. - AI-driven drug repurposing initiatives, led by organizations like Every Cure, are identifying new applications for FDA-approved drugs to address rare and underserved conditions. - Major pharmaceutical companies, including Novo Nordisk, are leveraging AI to strengthen supply chain resilience and enhance regulatory compliance, while the technology is also facilitating strategic M&A decisions.
